

INOVIO BIOMEDICAL CORP  
Form 8-K/A  
November 19, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K/A**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 26, 2009**

**INOVIO BIOMEDICAL CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**001-14888**  
(Commission  
File Number)

**33-0969592**  
(I.R.S. Employer  
Identification Number)

**11494 Sorrento Valley Road**  
**San Diego, California**  
(Address of Principal Executive Offices)

**92121-1318**  
(Zip Code)

Registrant's telephone number, including area code: **(858) 597-6006**

**N/A**

(Former name or former address, if changed since last report.)

Edgar Filing: INOVIO BIOMEDICAL CORP - Form 8-K/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Explanatory Note**

As described in the Current Report on Form 8-K of Inovio Biomedical Corporation ( Inovio ) dated October 26, 2009 (the Initial 8-K ), effective October 26, 2009, the Board of Directors (the Board ) of Inovio appointed Keith H. Wells, Ph.D. and David Williams as directors to hold office until Inovio s 2010 Annual Meeting of Stockholders and until their successors are elected and duly qualified.

Inovio is filing this amendment to the Initial 8-K to incorporate as part of the Initial 8-K the information set forth below under Item 5.02 as required by Instruction 2 to Item 5.02 of Form 8-K.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On November 17, 2009, Inovio s Board (i) appointed Dr. Wells to be a member of the Audit Committee of the Board and the Nomination and Corporate Governance Committee of the Board, and (ii) appointed Mr. Williams to be a member of the Compensation Committee of the Board and to be Chair of the Nomination and Corporate Governance Committee of the Board.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 19, 2009

INOVIO BIOMEDICAL CORPORATION

By:

/s/ Peter Kies  
Peter Kies, Chief Financial Officer